Nieuwe adviezen bij gebruik cenobamaat door risico op leverschade
Bij gebruik van cenobamaat voor epilepsie is er risico op leverschade. Medicijnautoriteit CBG geeft nieuwe adviezen om het risico op leverschade te verkleinen.
Read the original at the source: https://www.cbg-meb.nl/actueel/nieuws/2026/05/12/nieuwe-adviezen-bij-gebruik-cenobamaat-door-risico-op-leverschade
Officially imported this from Medicines Evaluation Board (CBG-MEB)’s own source. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
Provenance
- Organization
- Medicines Evaluation Board (CBG-MEB) — imported from official source
- Official source
- https://www.cbg-meb.nl/api/rss?query=%7B%22filters%22%3A%20%5B%7B%22field%22%3A%20%22information_type%22%2C%20%22values%22%3A%20%5B%22Nieuwsbericht%22%5D%2C%20%22type%22%3A%20%22any%22%7D%5D%2C%20%22resultSearchTerm%22%3A%20%22%22%2C%20%22pageTitle%22%3A%20%22Nieuws%22%7D RSS
- Imported
- October 03, 2026 20:38
- Versions
- 1 recorded
- Identity
doc-6a02ec126eab33dfe63a0eb4